Patients With Myelodysplastic Syndromes, Other Than Del(5)Q Syndrome, Exhibiting Del(5)Q Alone Or Associated With One Additional Chromosomal Abnormality Have Comparable Probability And Duration Of Response To Lenalidomide, With Patients Classified As Del(5)Q Syndrome

Abstract Background: Lenalidomide (Len) has been approved for anemic patients with Del(5)q syndrome and induces high response rates. However, patients exhibiting Del(5)q abnormality, but not classified as Del(5)q syndrome or presenting additional abnormalities over Del(5)q are not usually treated with lenalidomide and the experience on these patient groups is limited. Aim: We investigated response rates and duration of response to Len in 67 MDS patients, exhibiting Del(5)q, but not classified as Del(5)q syndrome and compared their clinical and laboratory features with those of 120 patients with Del(5)q syndrome, treated with Len the same time period. Data were collected from the Hellenic (Greek) National MDS Registry database. Methods: Patients were classified in four groups: Group-1 (N=120), with the typical Del(5)q syndrome, Group-2 (N=25), exhibiting Del(5)q alone, but not fulfilling criteria for Del(5)q syndrome, Group-3 (N=22), with Del(5)q plus 1 additional cytogenetic abnormality and Group 4 (n=20), exhibiting Del(5)q plus >1 additional cytogenetic abnormalities. Results were expressed on an “intention to treat” basis. Patients were considered evaluable for response if they had completed at least 2 cycles of Len treatment. Results: Group-2 patients were significantly younger, compared to those of all the remaining Groups (p Conclusion: Len may be highly effective, not only in patients with Del(5)q syndrome, but also in other MDS patients, exhibiting Del(5)q alone, or associated with 1 additional cytogenetic abnormality, even when excess of blasts is detected and might be considered as a treatment option in these MDS groups. Download : Download high-res image (105KB) Download : Download full-size image Disclosures Vassilakopoulos: Roche: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Celgene/GenesisPharma: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding. Katodritou: Janssen: Honoraria; Takeda: Honoraria, Research Funding; Amgen: Honoraria; Celgene: Honoraria, Research Funding. Pagoni: Gilead: Honoraria; Janssen: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Angelopoulou: Janssen: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria, Research Funding; BMS: Consultancy, Honoraria, Research Funding; Celgene/GenesisPharma: Consultancy, Honoraria, Research Funding. Labropoulou: Amgen: Honoraria; Celgene/GenesisPharma: Honoraria; Janssen: Honoraria. Terpos: Amgen: Honoraria, Other: SC member, Research Funding; Janssen: Honoraria, Research Funding; Genesis/Celgene: Honoraria, Other: DMC member, Research Funding; Takeda: Honoraria, Other: SC member; BMS: Honoraria; Abbvie: Honoraria; GSK: Honoraria.